Substituted benzimidazole compounds, compositions containing the same and uses thereof

By developing new deuterium-substituted benzimidazole compounds as MEK1/2 inhibitors, the problem of poor absorption, metabolism and excretion properties of existing MEK1/2 inhibitors has been solved, and effective treatment and better treatment of various cancers has been achieved. pharmacokinetic properties.

CN115490640BActive Publication Date: 2024-11-26SHENZHEN TARGETRX INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210665562.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-06-17
Filing Date
2022-06-14
Publication Date
2024-11-26
Estimated Expiration
2042-06-14

AI Technical Summary

Technical Problem

Due to poor absorption, distribution, metabolism and excretion properties of existing MEK1/2 inhibitors, the failure of clinical trials or the scope of application is limited, and rapid metabolism leads to the rapid removal of drugs from the body, resulting in poor treatment effects and increased side effects.

Method used

Develop a novel deuterium-substituted benzimidazole compound, which is a potent MEK1/2 inhibitor, with better solubility and metabolic stability, by inhibiting activated MEK for extensive antitumor activity and with other antitumor treatments Use the agent in combination.

Benefits of technology

A wide range of anti-tumor activities against a variety of cancer models were achieved, including melanoma, acute myeloid leukemia, etc., showing good pharmacokinetic performance and longer metabolic half-life, reducing side effects and improving treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115490640B_ABST
    Figure CN115490640B_ABST
Patent Text Reader

Abstract

The present invention provides a substituted benzimidazole compound and a composition containing the compound and its use. The substituted benzimidazole compound is a compound shown in formula (I) or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvent compound. The compound of formula (I) can be used as an effective MEK1 / 2 inhibitor, which can inhibit ERK phosphorylation by inhibiting activated MEK and show a wide range of anti-tumor activity in various cancer models. At the same time, the compound of the present invention can better treat various cancers in combination with other anti-tumor therapeutic agents. In addition to the inhibitory effect and efficacy, the compound of the present invention also shows better metabolic stability and / or pharmacokinetic properties. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular, relates to a substituted benzimidazole compound and a composition comprising the compound and its use. More specifically, the present invention relates to certain deuterium-substituted 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide and its derivatives and their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvent compounds. These deuterium-substituted compounds and their compositions can be used as potent selective inhibitors of MEK1 and MEK2 proteins, and can be used to treat diseases caused by MEK kinases, and these deuterium-substituted compounds have better ADME and pharmacokinetic properties. Background Art

[0002] The RAS / RAF / MEK / ERK kinase pathway is activated in more than 30% of human cancers. Activation of RAS GTPase (GTPase) proteins in response to growth factors, hormones, cytokines, etc. stimulates phosphorylation and activation of RAF kinases. These kinases then phosphorylate and activate intracellular protein kinases MEK1 and MEK2, which then phosphorylate and activate other protein kinases ERK1 and 2. This signaling pathway (also known as the mitogen-activated protein kinase (MAPK) pathway or cytoplasmic cascade) mediates the response of cells to growth signals. The fundamental function of this pathway is to link receptor activity at the cell membrane with cytoplasmic or nuclear-targeted modifications that control cell proliferation, differentiation, and survival.

[0003] The constitutive activation of this pathway is sufficient to induce cell transformation. The dysregulated activation of the MAPK pathway due to abnormal receptor tyrosine kinase activation, RAS mutations or RAF mutations is often found in human cancers and represents the main factor in determining abnormal growth control. In human malignancies, RAS mutations are common and have been identified in approximately 30% of cancers. The RAS family of GTPase proteins (proteins that convert guanosine triphosphate to guanosine diphosphate) transmits signals from activated growth factor receptors to downstream intracellular counterparts. Among the targets supplemented by active membrane-bound RAS, an important target is the RAF family of serine / threonine protein kinases. The RAF family consists of three related kinases (A-, B- and C-RAF), which act as downstream effectors of RAS. RAS-mediated RAF activation also triggers the activation of MEK1 and MEK2, followed by phosphorylation of ERK1 and ERK2 (extracellular signal-regulated kinases 1 and 2) on tyrosine-185 and threonine-183. Activated ERK1 and ERK2 change location and accumulate in the nucleus where they can phosphorylate various substrates including transcription factors that control cell growth and survival. Given the importance of the MAPK pathway in the development of human cancers, the kinase components of the signaling cascade are being incorporated as potentially important targets for modulating disease progression in cancer and other proliferative diseases.

[0004] MEK1 and MKE2 are members of a larger family of dual-specificity kinases that phosphorylate both threonine and tyrosine residues of various MAPKs. MEK1 and MEK2 are encoded by distinct genes, but they share a high degree of homology (80%) in the C-terminal catalytic kinase domain and in much of the N-terminal regulatory region. No oncogenic forms of MEK1 and MEK2 have been found in human cancers, but it has been shown that constitutive activation of MEK leads to cellular transformation. In addition to RAF, MEK can also be activated by other oncogenes. To date, the only known substrates for MEK1 and MEK2 are ERK1 and ERK2. In addition to the unique ability to phosphorylate both tyrosine and threonine residues, this unusual substrate specificity places MEK1 and MEK2 at critical points in the signaling cascade, which enables them to integrate many extracellular signals into the MAPK pathway.

[0005] The fundamental role and position of RAF in many signaling cascades has been demonstrated from studies using regulatory and markedly repressive RAF mutations in mammalian cells and in model organisms using biochemical and genetic techniques. RAF may have a prominent role in the development of certain tumors; for example, activated alleles of BRAF have been identified in ~70% of melanomas, 40% of papillary thyroid carcinomas, 30% of low-grade ovarian cancers, and 10% of colorectal cancers. Most BRAF mutations are found in the kinase domain, with a single substitution (V600E) accounting for at least 80%. Mutated BRAF proteins activate the RAS / RAF / MEK / ERK kinase pathway either through increased kinase activity of MEK or through activation of C-RAF.

[0006] Binimetinib (chemical name: 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide, with the following structural formula) is a potent, non-ATP competitive, highly selective MEK1 / 2 inhibitor developed by Array BioPharma, which can inhibit MEK, ERK phosphorylation and the growth of BRAF or KRAS mutant cancer cells at nanomolar concentrations. The U.S. Food and Drug Administration (FDA) granted binimetinib orphan drug status in November 2013, and approved it in combination with the BRAF inhibitor encorafenib in June 2018 for the treatment of patients with metastatic or unresectable melanoma with BRAF V600E / K mutations. It has been shown that the combination of BRAF inhibitors and MEK inhibitors can improve efficacy and may reduce toxic effects. In the National Comprehensive Cancer Network (NCCN) guidelines, BRAF inhibitor / MEK inhibitor combined with immunotherapy is recommended as first-line treatment for metastatic or unresectable melanoma.

[0007]

[0008]

[0009] Poor absorption, distribution, metabolism and / or excretion (ADME) properties are known to be the main reason for the failure of many candidate drugs in clinical trials. Many drugs currently on the market also limit their scope of application due to poor ADME properties. Rapid drug metabolism will cause many drugs that could have been highly effective in treating diseases to be difficult to make into medicines due to excessively rapid metabolism and clearance from the body. Although frequent or high-dose medication may solve the problem of rapid drug clearance, this method will bring about problems such as poor patient compliance, side effects caused by high-dose medication, and rising treatment costs. In addition, rapidly metabolized drugs may also expose patients to adverse toxic or reactive metabolites.

[0010] It is still a challenging task to find novel, effective, highly selective MEK1 / 2 inhibitors with good oral bioavailability and drugability. Therefore, the art still needs to develop compounds suitable for use as MEK1 / 2 inhibitors with selective inhibitory activity and / or better pharmacodynamics / pharmacokinetics, and the present invention provides such compounds. Summary of the invention

[0011] In view of the above technical problems, the present invention discloses a novel deuterium-substituted benzimidazole compound as an effective MEK1 / 2 inhibitor, which can inhibit ERK phosphorylation by inhibiting activated MEK, and exhibits a wide range of anti-tumor activity in various cancer models, including melanoma, acute myeloid leukemia, glioma, neurofibroma, non-small cell lung cancer, breast cancer, serous carcinoma, gastrointestinal stromal tumor, non-squamous lung cancer, colorectal cancer, biliary tract cancer, myeloma, etc. At the same time, the compounds of the present invention are combined with other anti-tumor therapeutic agents to treat various cancers. In addition to the inhibitory effect and efficacy, the compounds of the present invention also show good solubility and better metabolic stability and / or pharmacokinetic properties.

[0012] To this end, the present invention adopts the following technical solutions:

[0013] The first aspect of the present invention provides a compound of formula (I):

[0014]

[0015] in,

[0016] Y1, Y2, Y3, Y4 and Y5 are each independently selected from hydrogen, deuterium or halogen;

[0017] R1, R2, R3 and R4 are each independently selected from hydrogen or deuterium;

[0018] X is each independently selected from CH3, CD3, CHD2 or CH2D;

[0019] Provided that the above compound contains at least one deuterium atom;

[0020] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0021] On the other hand, the present invention provides a pharmaceutical composition containing a compound of the present invention or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvent compound and a pharmaceutically acceptable excipient. In a specific embodiment, the compound of the present invention is provided in an effective amount in the pharmaceutical composition. In a specific embodiment, the compound of the present invention is provided in a therapeutically effective amount. In a specific embodiment, the compound of the present invention is provided in a preventive effective amount. In a specific embodiment, the pharmaceutical composition further comprises an additional therapeutic agent. In a specific embodiment, the additional therapeutic agent is selected from one or more of a BRAF inhibitor, an EGFR inhibitor, an EGFR antibody, an immune checkpoint inhibitor or a CDK4 / 6 inhibitor. In a specific embodiment, the BRAF inhibitor is selected from vemurafenib, dabrafenib, encorafenib, (S)-methyl-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(methyl-d3)-(1-((4-( 3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamic acid methyl ester, (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamic acid methyl ester. In a specific embodiment, the EGFR inhibitor is selected from gefitinib, erlotinib, afatinib, dacomitinib, lapatinib, osimertinib, ametinib, vometinib, CO-1686, WZ4002, PD153035, PF00299804. In a specific embodiment, the EGFR antibody is selected from cetuximab, panitumumab, necituzumab.In a specific embodiment, the immune checkpoint inhibitor is selected from pembrolizumab, ipilimumab and nivolumab, atezolizumab, avelumab, durvalumab, pidilzumab. In a specific embodiment, the CDK4 / 6 inhibitor is selected from palbociclib, ribociclib, abemaciclib.

[0022] On the other hand, the present invention provides a method for preparing the pharmaceutical composition as described above, comprising the following steps: mixing a pharmaceutically acceptable excipient with the compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate to form a pharmaceutical composition.

[0023] In another aspect, the present invention further provides a method for treating a MEK kinase-mediated disease, which comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention.

[0024] In a specific embodiment, the MEK kinase-mediated disease is melanoma, acute myeloid leukemia, glioma, neurofibroma, non-small cell lung cancer, breast cancer, serous carcinoma, gastrointestinal stromal tumor, non-squamous lung cancer, colorectal cancer, biliary tract cancer, myeloma. In a specific embodiment, the melanoma is selected from melanoma with BRAF V600 mutation. In a specific embodiment, the colorectal cancer is selected from colorectal cancer with BRAF V600 mutation. In a specific embodiment, the BRAF V600 mutation is selected from BRAF V600E mutation or BRAF V600K mutation. In a specific embodiment, the neurofibroma is selected from neurofibromatosis type 1 (NF1) or plexiform neurofibroma;

[0025] Other objects and advantages of the present invention will be apparent to those skilled in the art from the following detailed description, examples and claims.

[0026] definition

[0027] Herein, unless otherwise specified, "deuterated" means that one or more hydrogen atoms in a compound or group are replaced by deuterium; deuterated can be monosubstituted, disubstituted, polysubstituted or fully substituted. The term "one or more deuterated" and "one or more deuterated" can be used interchangeably.

[0028] As used herein, unless otherwise specified, a "non-deuterated compound" refers to a compound containing deuterium atoms at a ratio not higher than the natural deuterium isotope content (0.015%).

[0029] As used herein, the term "subject" includes, but is not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or older adults)) and / or non-human animals, e.g., mammals, e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In some embodiments, the subject is a human. In other embodiments, the subject is a non-human animal.

[0030] "Disease," "disorder," and "condition" are used interchangeably herein.

[0031] As used herein, and unless otherwise indicated, the terms "treat," "treatment," "treating ...

[0032] Generally, an "effective amount" of a compound refers to an amount sufficient to cause a target biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of the compounds of the invention may vary depending on factors such as the biological target, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and symptoms of the subject. An effective amount includes both therapeutic and prophylactic treatment effective amounts.

[0033] Unless otherwise specified, a "therapeutically effective amount" of a compound as used herein is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with the disease, disorder, or condition. A therapeutically effective amount of a compound refers to an amount of a therapeutic agent, used alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" may include an amount that improves overall treatment, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of other therapeutic agents.

[0034] Unless otherwise specified, a "prophylactically effective amount" of a compound as used herein is an amount sufficient to prevent a disease, disorder, or condition, or an amount sufficient to prevent one or more symptoms associated with a disease, disorder, or condition, or an amount to prevent the recurrence of a disease, disorder, or condition. A prophylactically effective amount of a compound refers to an amount of a therapeutic agent used alone or in combination with other agents that provides a prophylactic benefit in the process of preventing a disease, disorder, or condition. The term "prophylactically effective amount" may include an amount that improves overall prevention, or an amount that enhances the prophylactic efficacy of other prophylactic agents.

[0035] "Combination" and related terms refer to simultaneous or sequential administration of therapeutic agents of the invention. For example, a compound of the invention can be administered simultaneously or sequentially with another therapeutic agent in separate unit dosage forms, or simultaneously with another therapeutic agent in a single unit dosage form. DETAILED DESCRIPTION

[0036] Compound

[0037] Herein, "compounds of the present invention" refers to the compounds of the following formula (I) and formula (II) or their tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates.

[0038] In one embodiment, the present invention relates to compounds of formula (I):

[0039]

[0040]

[0041] in,

[0042] Y1, Y2, Y3, Y4 and Y5 are each independently selected from hydrogen, deuterium or halogen;

[0043] R1, R2, R3 and R4 are each independently selected from hydrogen or deuterium;

[0044] X is selected from CH3, CD3, CHD2 or CH2D;

[0045] Provided that the above compound contains at least one deuterium atom;

[0046] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0047] In a specific embodiment, the deuterium isotope content of deuterium at the deuterated position is at least 0.015% greater than the natural deuterium isotope content, preferably greater than 30%, more preferably greater than 50%, more preferably greater than 75%, more preferably greater than 95%, and more preferably greater than 99%.

[0048] Specifically, in the present invention, the deuterium isotope content of each deuterated position of Y1, Y2, Y3, Y4, Y5, R1, R2, R3, R4 and X is at least greater than 0.015% of the natural isotope content, more preferably greater than 1%, more preferably greater than 5%, more preferably greater than 10%, more preferably greater than 15%, more preferably greater than 20%, more preferably greater than 25%, more preferably greater than 30%, more preferably greater than 35%, more preferably greater than 40%, more preferably greater than 45%, more preferably greater than 50%, more preferably greater than 55%, more preferably greater than 60%, more preferably greater than 65%, more preferably greater than 70%, more preferably greater than 75%, more preferably greater than 80%, more preferably greater than 85%, more preferably greater than 90%, more preferably greater than 95%, more preferably greater than 99%.

[0049] In another specific embodiment, the compound of the present invention contains at least one deuterium atom, more preferably two deuterium atoms, more preferably three deuterium atoms, more preferably four deuterium atoms, more preferably five deuterium atoms, more preferably six deuterium atoms, more preferably seven deuterium atoms, more preferably eight deuterium atoms, more preferably nine deuterium atoms, more preferably ten deuterium atoms, more preferably eleven deuterium atoms, more preferably twelve deuterium atoms.

[0050] In another specific embodiment, "Y1, Y2, Y3, Y4 and Y5 are each independently selected from hydrogen, deuterium or halogen" includes Y1 selected from hydrogen, deuterium or halogen, Y2 selected from hydrogen, deuterium or halogen, Y3 selected from hydrogen, deuterium or halogen, and so on, until Y5 is selected from hydrogen, deuterium or halogen. More specifically, it includes Y1 is hydrogen, Y1 is deuterium or Y1 is halogen (F, Cl, Br or I), Y2 is hydrogen, Y2 is deuterium or Y2 is halogen (F, Cl, Br or I), Y3 is hydrogen, Y3 is deuterium or Y3 is halogen (F, Cl, Br or I), and so on, until Y5 is hydrogen, Y5 is deuterium or Y5 is halogen (F, Cl, Br or I).

[0051] In another specific embodiment, "R1, R2, R3 and R4 are each independently selected from hydrogen or deuterium" includes the technical solution that R1 is selected from hydrogen or deuterium, R2 is selected from hydrogen or deuterium, R3 is selected from hydrogen or deuterium, and R4 is selected from hydrogen or deuterium. More specifically, it includes the technical solution that R1 is hydrogen or R1 is deuterium, R2 is hydrogen or R2 is deuterium, R3 is hydrogen or R3 is deuterium, and R4 is hydrogen or R4 is deuterium.

[0052] In another specific embodiment, "X is selected from CH3, CD3, CHD2 or CH2D" includes the technical solutions that X is CH3, X is CD3, X is CHD2 or X is CH2D.

[0053] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, Y2, Y3, Y4, Y5, R1, R2, R3 and R4 are as defined above.

[0054] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R1 and R2 are deuterium, and Y1, Y2, Y3, Y4, Y5, R3, R4 and X are as defined above.

[0055] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R3 and R4 are deuterium, and Y1, Y2, Y3, Y4, Y5, R1, R2 and X are as defined above.

[0056] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R1, R2, R3 and R4 are deuterium, and Y1, Y2, Y3, Y4, Y5 and X are as defined above.

[0057] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1 is deuterium, and Y2, Y3, Y4, Y5, R1, R2, R3, R4 and X are as defined above.

[0058] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1 is deuterium, and Y2, Y3, Y4, Y5, R1, R2, R3 and R4 are as defined above.

[0059] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R1 and R2 are deuterium, and Y1, Y2, Y3, Y4, Y5, R3 and R4 are as defined above.

[0060] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R3 and R4 are deuterium, and Y1, Y2, Y3, Y4, Y5, R1 and R2 are as defined above.

[0061] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R1, R2, R3 and R4 are deuterium, and Y1, Y2, Y3, Y4 and Y5 are as defined above.

[0062] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R1 and R2 are deuterium, and Y2, Y3, Y4, Y5, R3, R4 and X are as defined above.

[0063] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R3 and R4 are deuterium, and Y2, Y3, Y4, Y5, R1, R2 and X are as defined above.

[0064] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R1, R2, R3 and R4 are deuterium, and Y2, Y3, Y4, Y5 and X are as defined above.

[0065] In some embodiments of the general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R1 and R2 are deuterium, and Y2, Y3, Y4, Y5, R3 and R4 are as defined above.

[0066] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R3 and R4 are deuterium, and Y2, Y3, Y4, Y5, R1 and R2 are as defined above.

[0067] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R1, R2, R3 and R4 are deuterium, and Y2, Y3, Y4 and Y5 are as defined above.

[0068] In another embodiment, the present invention relates to compounds of formula (II):

[0069]

[0070] in,

[0071] Y1 is selected from hydrogen, deuterium or halogen;

[0072] R1, R2, R3 and R4 are each independently selected from hydrogen or deuterium;

[0073] X is selected from CH3, CD3, CHD2 or CH2D;

[0074] Provided that the above compound contains at least one deuterium atom;

[0075] or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof.

[0076] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R1, R2, R3 and R4 are as defined above.

[0077] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R1 and R2 are deuterium, and Y1, R3, R4 and X are as defined above.

[0078] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R3 and R4 are deuterium, and Y1, R1, R2 and X are as defined above.

[0079] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein R1, R2, R3 and R4 are deuterium, and Y1 and X are as defined above.

[0080] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1 is deuterium, and R1, R2, R3, R4 and X are as defined above.

[0081] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1 is deuterium, and R1, R2, R3 and R4 are as defined above.

[0082] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R1 and R2 are deuterium, and Y1, R3, R4 and Y5 are as defined above.

[0083] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R3 and R4 are deuterium, and Y1, R1 and R2 are as defined above.

[0084] In some embodiments of general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, R1, R2, R3 and R4 are deuterium, and Y1 is as defined above.

[0085] In some embodiments of general formula (I), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R1 and R2 are deuterium, and R3, R4 and X are as defined above.

[0086] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R3 and R4 are deuterium, and R1, R2 and X are as defined above.

[0087] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein Y1, R1, R2, R3 and R4 are deuterium, and X is as defined above.

[0088] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R1 and R2 are deuterium, and R3 and R4 are as defined above.

[0089] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R3 and R4 are deuterium, and R1 and R2 are as defined above.

[0090] In some embodiments of the general formula (II), preferably, the present invention relates to the above-mentioned compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, wherein X is CD3, Y1, R1, R2, R3 and R4 are deuterium.

[0091] As a preferred embodiment of the present invention, the compound, or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, is selected from any of the following compounds:

[0092]

[0093]

[0094]

[0095]

[0096] The compounds of the present invention may include one or more asymmetric centers and may therefore exist in a variety of stereoisomeric forms, for example, enantiomers and / or diastereoisomeric forms. For example, the compounds of the present invention may be individual enantiomers, diastereomers or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from the mixture by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis.

[0097] Those skilled in the art will appreciate that organic compounds can form complexes with solvents in which they react or from which they precipitate or crystallize. These complexes are referred to as "solvates". When the solvent is water, the complex is referred to as a "hydrate". The present invention encompasses all solvates of the compounds of the present invention.

[0098] The term "solvate" refers to a form of a compound or its salt that is combined with a solvent, usually formed by a solvent decomposition reaction. This physical association may include hydrogen bonding. Conventional solvents include water, methanol, ethanol, acetic acid, DMSO, THF, ether, etc. The compounds described herein can be prepared, for example, in a crystalline form and can be solvated. Suitable solvates include pharmaceutically acceptable solvates and further include stoichiometric solvates and non-stoichiometric solvates. In some cases, the solvate will be able to separate, for example, when one or more solvent molecules are incorporated into the crystal lattice of the crystalline solid. "Solvate" includes solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates and methanolates.

[0099] The term "hydrate" refers to a compound that is combined with water. Generally, the ratio of the number of water molecules contained in the hydrate of a compound to the number of molecules of the compound in the hydrate is determined. Therefore, the hydrate of a compound can be represented by, for example, the general formula R·xH2O, where R is the compound, and x is a number greater than 0. A given compound can form more than one type of hydrate, including, for example, a monohydrate (x is 1), a lower hydrate (x is a number greater than 0 and less than 1, for example, a hemihydrate (R·0.5H2O)) and a polyhydrate (x is a number greater than 1, for example, a dihydrate (R·2H2O) and a hexahydrate (R·6H2O)).

[0100] The compounds of the present invention can be in amorphous or crystalline form (polymorph). In addition, the compounds of the present invention can exist in one or more crystalline forms. Therefore, the present invention includes all amorphous or crystalline forms of the compounds of the present invention within its scope. The term "polymorph" refers to the crystalline form (or its salt, hydrate or solvate) of a compound with a specific crystal packing arrangement. All polymorphs have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, photoelectric properties, stability and solubility. Recrystallization solvents, crystallization rates, storage temperatures and other factors can lead to a dominant crystalline form. The various polymorphs of a compound can be prepared by crystallization under different conditions.

[0101] The present invention also includes isotopically labeled compounds which are identical to those of the present invention but for which one or more atoms have been replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number normally found in nature. Examples of isotopes that can be introduced into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine and chlorine, e.g. 2 H. 3 H. 13 C. 11 C. 14 C. 15 N. 18 O. 17 O. 31 P. 32 P. 35 S. 18 F and 36 Cl. Compounds of the present invention containing the above isotopes and / or other isotopes of other atoms, their prodrugs and pharmaceutically acceptable salts of the compounds or prodrugs are within the scope of the present invention. Certain isotopically labeled compounds of the present invention, such as those in which a radioactive isotope (e.g. 3 H and 14 C) can be used for drug and / or substrate tissue distribution assays. 3 H and carbon-14, i.e. 14 C isotopes are particularly preferred because they are easy to prepare and detect. 2 H, because higher metabolic stability can provide therapeutic benefits, such as prolonged half-life in vivo or reduced dosage requirements, and thus may be preferred in some cases. Isotope-labeled compounds of formula (I) of the present invention and their prodrugs can generally be prepared by replacing non-isotope-labeled reagents with readily available isotope-labeled reagents when carrying out the processes disclosed in the following schemes and / or Examples and Preparation Examples.

[0102] In addition, prodrugs are also included in the context of the present invention. The term "prodrug" as used herein refers to a compound that is converted into its active form having a medical effect in vivo by, for example, hydrolysis in the blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the ACSSymposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19 (2) 115-130, each of which is incorporated herein by reference.

[0103] Prodrugs are any covalently bonded compounds of the present invention that release the parent compound in vivo when such prodrugs are administered to a patient. Prodrugs are usually prepared by modifying functional groups, and the modification is carried out in a manner that allows the modification to be cleaved to produce the parent compound by conventional manipulation or in vivo. Prodrugs include, for example, compounds of the present invention in which hydroxyl, amino or sulfhydryl groups are bonded to any group, which can be cleaved to form hydroxyl, amino or sulfhydryl groups when administered to a patient. Therefore, representative examples of prodrugs include, but are not limited to, acetate / amide, formate / amide and benzoate / amide derivatives of hydroxyl, sulfhydryl and amino functional groups of compounds of formula (I). In addition, in the case of carboxylic acid (-COOH), esters such as methyl esters, ethyl esters, etc. can be used. Esters themselves can be active and / or can be hydrolyzed under human body conditions. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those groups that are easily decomposed in the human body to release the parent acid or its salt.

[0104] Methods for preparing the compounds of the present invention

[0105] The compounds of the present invention (including salts thereof) can be prepared using known organic synthesis techniques and can be synthesized according to any of a variety of possible synthetic pathways (such as those in the scheme below). The reaction for preparing the compounds of the present invention can be carried out in a suitable solvent, and a technician in the field of organic synthesis can easily select a solvent. A suitable solvent can be substantially unreactive with a starting material (reactant), an intermediate or a product at a temperature for carrying out the reaction (e.g., a temperature within the range of the solvent freezing temperature to the solvent boiling temperature). A given reaction can be carried out in a solvent or a mixture of more than one solvent. A technician can select a solvent for a specific reaction step according to the specific reaction step.

[0106] The preparation of the compounds of the present invention may involve the protection and removal of different chemical groups. One skilled in the art can easily determine whether protection and removal of protection and the selection of appropriate protecting groups are required. The chemical properties of protecting groups can be found, for example, in Wuts and Greene, Protective Groups in Organic Synthesis, 4th Edition, John Wiley & Sons: New Jersey, (2006), which is incorporated herein by reference in its entirety.

[0107] The compounds of the present invention can be reacted with an optically active resolving agent to form a pair of diastereomeric compounds, separate diastereoisomers and recycle the enantiomers of optical purity to prepare their single stereoisomers. The diastereomeric derivatives of the compounds of the present invention can be used to carry out the separation of enantiomers, preferably dissociable complexes (e.g., crystalline diastereomeric salts). Diastereomers have significantly different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.), and can be easily separated by the advantages of these dissimilarity. Diastereomers can be separated by chromatography, preferably by separation / resolving techniques based on differences in solubility. Then, by any practical means that will not racemize, the optically pure enantiomer is recovered, together with the resolving agent. A more detailed description of techniques suitable for resolving stereoisomers of compounds starting from racemic mixtures can be found in Jean Jacques, Andre Collet, Samuel H. Wilen, "Enantiomers, Racemates and Resolutions", John Wiley And Sons, Inc., 1981.

[0108] The reaction can be monitored by any suitable method known in the art. For example, the reaction can be monitored by spectroscopic means such as nuclear magnetic resonance (NMR) spectroscopy (e.g. 1 H or 13C), infrared (IR) spectroscopy, spectrophotometry (e.g., UV-visible), mass spectrometry (MS), or by chromatographic methods such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC).

[0109] Pharmaceutical compositions, preparations and kits

[0110] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a preventive effective amount of a compound of the present invention.

[0111] The pharmaceutically acceptable excipient used in the present invention refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated together. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition of the present invention include (but are not limited to) ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin.

[0112] The present invention also includes a kit (e.g., a pharmaceutical package). The kit provided may include a compound of the invention, other therapeutic agents, and a first and second container (e.g., a vial, an ampoule, a bottle, a syringe, and / or a dispersible package or other suitable container) containing the compound of the invention and other therapeutic agents. In some embodiments, the kit provided may also optionally include a third container containing a pharmaceutical excipient for diluting or suspending the compound of the invention and / or other therapeutic agents. In some embodiments, the compound of the invention and other therapeutic agents provided in the first container and the second container are combined to form a unit dosage form.

[0113] The following formulation examples illustrate representative pharmaceutical compositions that can be prepared according to the present invention. However, the present invention is not limited to the following pharmaceutical compositions.

[0114] Exemplary Formulation 1 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 0.3-30 mg tablets (each tablet containing 0.1-10 mg of active compound) in a tablet press.

[0115] Exemplary Formulation 2 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 30-90 mg tablets (each tablet contains 10-30 mg of active compound) in a tablet press.

[0116] Exemplary Formulation 3 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 90-150 mg tablets (each tablet contains 30-50 mg of active compound) in a tablet press.

[0117] Exemplary Formulation 4 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 150-240 mg tablets (each tablet contains 50-80 mg of active compound) in a tablet press.

[0118] Exemplary Formulation 5 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (each tablet contains 80-90 mg of active compound) in a tablet press.

[0119] Exemplary Formulation 6 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 270-450 mg tablets (each tablet contains 90-150 mg of active compound) in a tablet press.

[0120] Exemplary Formulation 7 - Tablets: A compound of the invention in dry powder form can be mixed with a dry gel binder in a weight ratio of about 1:2. A smaller amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (each tablet contains 150-300 mg of active compound) in a tablet press.

[0121] Exemplary Formulation 8 - Capsules: A compound of the invention in dry powder form can be mixed with a starch diluent in a weight ratio of about 1 : 1. The mixture is filled into 250 mg capsules (each capsule contains 125 mg of active compound).

[0122] Exemplary Formulation 9 - Liquid: The compounds of the invention (125 mg) may be mixed with sucrose (1.75 g) and xanthan gum (4 mg), and the resulting mixture may be blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a pre-prepared aqueous solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, 50 mg). Sodium benzoate (10 mg), flavoring agents, and coloring agents are diluted with water and added under stirring. Sufficient water may then be added to give a total volume of 5 mL.

[0123] Exemplary Formulation 10 - Injection: The compound of the invention may be dissolved or suspended in a buffered sterile saline injectable aqueous medium to a concentration of about 5 mg / mL.

[0124] Drug administration

[0125] Pharmaceutical composition provided by the invention can be administered by many ways, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration, rectal administration, nasal administration, oral administration, vaginal administration, administration by implant or other modes of administration. For example, parenteral administration used herein includes subcutaneous administration, intradermal administration, intravenous administration, intramuscular administration, intraarticular administration, intraarterial administration, intrasynovial cavity administration, intrasternal administration, intrathecal administration, intralesional administration and intracranial injection or infusion technology.

[0126] Generally, an effective amount of the compounds provided herein is administered. The amount of the compound actually administered can be determined by a physician according to the relevant circumstances, including the condition being treated, the route of administration selected, the compound actually administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, and the like.

[0127] When used to prevent the conditions described herein, the compounds provided herein are administered to a subject at risk of developing the condition, typically based on the advice of a physician and under the supervision of a physician, at dosage levels as described above. Subjects at risk of developing a specific condition typically include those with a family history of the condition, or those identified by genetic testing or screening as being particularly susceptible to developing the condition.

[0128] The pharmaceutical compositions provided herein can also be administered over a long period of time ("chronic administration"). Chronic administration refers to administration of a compound or a pharmaceutical composition thereof over a long period of time, e.g., 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or administration may continue indefinitely, e.g., for the rest of the subject's life. In some embodiments, chronic administration is intended to provide a constant level of the compound in the blood over a long period of time, e.g., within a therapeutic window.

[0129] Various methods of administration can be used to further deliver the pharmaceutical composition of the present invention. For example, in some embodiments, the pharmaceutical composition can be administered by push injection, for example, in order to increase the concentration of the compound in the blood to an effective level. The push dose depends on the target systemic level of the active component through the body, for example, the intramuscular or subcutaneous push dose slowly releases the active component, and the push delivered directly to the vein (for example, by IV intravenous drip) can be delivered more quickly, so that the concentration of the active component in the blood is quickly increased to an effective level. In other embodiments, the pharmaceutical composition can be given in a continuous infusion form, for example, by IV intravenous drip, so as to provide a steady-state concentration of the active component in the subject's body. In addition, in other embodiments, the pharmaceutical composition of the push dose can be first given, and then continuous infusion.

[0130] Oral compositions can be in the form of bulk liquid solutions or suspensions or bulk powders. However, more generally, in order to facilitate accurate dosing, the composition is provided in unit dosage form. The term "unit dosage form" refers to a physical discrete unit suitable as a unit dose for human patients and other mammals, each unit containing a predetermined amount of active substances suitable for producing the desired therapeutic effect and a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of liquid compositions, or pills, tablets, capsules, etc. in the case of solid compositions. In such compositions, the compound is usually a relatively small component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), and the remainder is various carriers or excipients and processing aids useful for forming the desired administration form.

[0131] For oral dosage, a representative regimen is one to five oral doses per day, especially two to four oral doses, typically three oral doses. Using these dosage modes, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, and preferred doses each provide about 0.1 to about 10 mg / kg, especially about 1 to about 5 mg / kg.

[0132] In order to provide blood levels similar to those using an injectable dose, or lower blood levels than using an injectable dose, a transdermal dose is generally selected in an amount of about 0.01 to about 20% by weight, preferably about 0.1 to about 20% by weight, preferably about 0.1 to about 10% by weight, and more preferably about 0.5 to about 15% by weight.

[0133] From about 1 to about 120 hours, especially 24 to 96 hours, the injected dosage level is in the range of about 0.1 mg / kg / hour to at least 10 mg / kg / hour. In order to obtain sufficient steady state levels, a preload bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be given. For a 40 to 80 kg human patient, the maximum total dose cannot exceed about 2 g / day.

[0134] Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous carrier and buffers, suspending and dispersing agents, colorants, flavoring agents, etc. Solid forms may include, for example, any of the following components, or compounds of a similar nature: binders, such as microcrystalline cellulose, tragacanth, or gelatin; excipients, such as starch or lactose, disintegrants, such as alginic acid, Primogel, or corn starch; lubricants, such as magnesium stearate; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or flavoring agents, such as peppermint, methyl salicylate, or orange flavoring.

[0135] Injectable compositions are typically based on injectable sterile saline or phosphate buffered saline, or other injectable excipients known in the art. As previously mentioned, in such compositions, the active compound is typically a minor component, often about 0.05 to 10% by weight, and the remainder is an injectable excipient, etc.

[0136] Typically, transdermal compositions are formulated as topical ointments or creams containing active ingredients. When formulated as an ointment, the active ingredient is typically combined with a paraffin or water-miscible ointment base. Alternatively, the active ingredient can be formulated as an ointment together with, for example, an oil-in-water cream base. Such transdermal formulations are well known in the art and typically include other components for enhancing the stable skin penetration of the active ingredient or formulation. All such known transdermal formulations and components are included within the scope provided by the invention.

[0137] The compounds of the invention may also be administered by transdermal means. Thus, transdermal administration may be achieved using patches of the reservoir or porous membrane type, or a variety of solid matrices.

[0138] The above components for oral administration, injection or topical administration are representative only. Other materials and processing techniques are described in Remington's Pharmaceutical Sciences, 17th edition, 1985, Mack Publishing Company, Easton, Pennsylvania, Part 8, which is incorporated herein by reference.

[0139] The compounds of the invention may also be administered in sustained release form or from a sustained release delivery system. Descriptions of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0140] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation comprises water. In another embodiment, the formulation comprises a cyclodextrin derivative. The most common cyclodextrins are α-, β- and γ-cyclodextrins consisting of 6, 7 and 8 α-1,4-linked glucose units, respectively, which optionally include one or more substituents on the linked sugar moiety, including but not limited to: methylated, hydroxyalkylated, acylated and sulfoalkyl ether substitutions. In some embodiments, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, for example, sulfobutyl ether β-cyclodextrin, also known as Captisol. See, for example, US5,376,645. In some embodiments, the formulation includes hexapropyl-β-cyclodextrin (e.g., in water, 10-50%).

[0141] Indications

[0142] The present invention provides a method for treating a disease in a subject, such as a MEK kinase-mediated disease, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention. The treatment method may also be combined with other therapies such as radiotherapy and chemotherapy.

[0143] In specific embodiments, MEK kinase-mediated diseases include inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorders, neurological disorders, fibrotic disorders, proliferative disorders, hyperproliferative disorders, tumors, leukemias, neoplasms, cancers, malignancies, metabolic diseases, and malignant diseases.

[0144] The present invention also provides a method for treating MEK kinase-mediated inflammatory diseases, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention.

[0145] In specific embodiments, the MEK kinase-mediated inflammatory disease comprises rheumatoid arthritis or multiple sclerosis.

[0146] The present invention also provides a method for treating MEK kinase-mediated proliferative diseases, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention.

[0147] In specific embodiments, the MEK kinase-mediated proliferative disease comprises cancer, psoriasis, restenosis, an autoimmune disease, or atherosclerosis.

[0148] The present invention also provides a method for treating MEK kinase-mediated cancer, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention.

[0149] In specific embodiments, MEK kinase-mediated cancers include melanoma (e.g., melanoma with BRAF V600 mutation), acute myeloid leukemia, glial carcinoma, neurofibroma (e.g., neurofibromatosis type 1 (NF1) or plexiform neurofibroma), non-small cell lung cancer, breast cancer, serous carcinoma, gastrointestinal stromal tumor, non-squamous lung cancer, colorectal cancer (e.g., colorectal cancer with BRAF V600 mutation), biliary tract cancer, myeloma.

[0150] The present invention describes inhibitors of MEK kinases for the treatment of diseases driven by overactivation, aberrant activation, constitutive activation, gain-of-function mutations of MEK kinases and / or substrate kinases including but not limited to ERK. Such diseases encompass hyperproliferative diseases including but not limited to psoriasis, keloids, hyperplasia of the skin, benign prostatic hyperplasia (BPH), solid tumors such as respiratory tract (including but not limited to small cell and non-small cell lung cancer), brain (including but not limited to gliomas, neurofibromas, plexiform neurofibromas, medulloblastomas, ependymomas, neuroectodermal and pineal tumors), breast (including but not limited to invasive ductal carcinoma, invasive lobular carcinoma, ductal and lobular carcinoma in situ), reproductive organs (including but not limited to prostate cancer, testicular cancer, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer and uterine sarcoma), digestive tract (including but not limited to prostate cancer, testicular cancer, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer and uterine sarcoma), Cancers of the esophagus (including but not limited to cancers of the esophagus, colon, colorectum, stomach, gallbladder, pancreas, rectum, anus, small intestine, and salivary glands), urethra (including but not limited to cancers of the bladder, ureter, kidney, renal, urethra, and renal papillary carcinomas), eye (including but not limited to intraocular melanoma and retinoblastoma), liver (including but not limited to hepatocellular carcinoma and bile duct cancer), skin (including but not limited to melanoma, squamous cell carcinoma, Kapos sarcoma, Merkel cell skin cancer, non-melanoma skin cancer), head and neck (including but not limited to cancers of the larynx, nasopharynx, hypopharynx, oropharynx, lip and oral cavity, and squamous cell carcinoma), thyroid, parathyroid glands, and their metastases. Hyperproliferative diseases also include leukemias (including but not limited to acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia and hairy cell leukemia), sarcomas (including but not limited to soft tissue sarcoma, osteosarcoma, lymphosarcoma, rhabdomyosarcoma) and lymphomas (including but not limited to non-Hodgkin's lymphoma, AIDS-related lymphoma, cutaneous T-cell lymphoma, Burkitt's lymphoma, Hodgkin's disease and lymphomas of the central nervous system).

[0151] The present invention describes inhibitors of MEK kinase for use in certain diseases involving abnormal regulation of mitogen extracellular kinase activity, including but not limited to hepatomegaly, heart failure, cardiac hypertrophy, diabetes, stroke, Alzheimer's disease, cystic fibrosis, septic shock or asthma.

[0152] The present invention describes inhibitors of MEK kinase for use in treating diseases and disorders associated with aberrant, abnormal and / or excessive angiogenesis. Such angiogenesis-related disorders include, but are not limited to, tumor growth and metastasis, ischemic retinal vein occlusion, diabetic retinopathy, macular degeneration, neovascular glaucoma, psoriasis, inflammation, rheumatoid arthritis, vascular graft restenosis, restenosis, and in-stent restenosis.

[0153] The present invention also provides a method for treating acute myeloid leukemia, comprising administering to the subject a compound of the present invention or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition of the present invention. In a specific embodiment, the acute myeloid leukemia is relapsed and / or refractory acute myeloid leukemia.

[0154] The present invention also provides a method for treating glioma, comprising administering to the subject the compound of the present invention or its tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate, or the pharmaceutical composition of the present invention.

[0155] The present invention also provides a method for treating neurofibroma, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention. In a specific embodiment, the neurofibroma is selected from neurofibromatosis type 1 (NF1) or plexiform neurofibroma.

[0156] The present invention also provides a method for treating serous carcinoma, comprising administering to the subject a compound of the present invention or its tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate, or a pharmaceutical composition of the present invention. In a specific embodiment, the serous carcinoma is selected from recurrent or persistent low-grade ovarian, fallopian tube or primary peritoneal serous carcinoma.

[0157] Combination therapy

[0158] The compounds of the present invention can be used alone or in combination with other therapeutic agents. Combination therapy according to the present invention therefore includes administering at least one compound of the present invention and using at least one other pharmaceutically active agent. One or more compounds of the present invention and one or more other pharmaceutically active agents can be administered together or separately, and when administered separately, they can be administered simultaneously or sequentially in any order. The amount and relative timing of administration of one or more compounds of the present invention and one or more other pharmaceutically active agents will be selected to achieve the desired combination therapy effect. Specifically:

[0159] The present invention provides a method for treating BRAF kinase-mediated cancer, comprising administering to the subject a compound of the present invention in combination with a BRAF inhibitor (each optionally in a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate), and optionally a third therapeutic agent.

[0160] In a specific embodiment, the BRAF inhibitor is selected from vemurafenib, dabrafenib, encorafenib or the following compounds disclosed in WO 2020 / 011141 A1:

[0161] Compounds disclosed in WO 2020 / 011141 A1

[0162] Preferably, the BRAF inhibitor is selected from vemurafenib, dabrafenib, encorafenib, and the following compounds disclosed in WO 2020 / 011141 A1:

[0163] (S)-methyl-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0164] (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0165] (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0166] Methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0167] (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0168] (R)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0169] Methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0170] (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0171] (R)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate.

[0172] More preferably, the BRAF inhibitor is selected from vemurafenib, dabrafenib, encorafenib, and the following compounds disclosed in WO 2020 / 011141 A1:

[0173] (S)-methyl-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0174] (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0175] (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate,

[0176] (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate,

[0177] (S)-methyl(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamate.

[0178] In certain embodiments, the method of treating a BRAF kinase-mediated cancer does not comprise a third therapeutic agent.

[0179] In a specific embodiment, the method for treating BRAF kinase-mediated cancer comprises a third therapeutic agent. In a specific embodiment, the third therapeutic agent is selected from immune checkpoint inhibitors, for example, pembrolizumab, ipilimumab and nivolumab, atezolizumab, avelumab, durvalumab, pidilzumab, PDR-001 (BAP049-Clone-E, disclosed in and used in WO 2017 / 019896); preferably, for example, pembrolizumab, ipilimumab and nivolumab. In a specific embodiment, the third therapeutic agent is selected from an EGFR antibody, for example, cetuximab, panitumumab, necitumumab; preferably, for example, cetuximab. In a specific embodiment, the third therapeutic agent is a mitotic inhibitor, for example, a CDK4 / 6 inhibitor; preferably, for example, palbociclib, ribociclib, abemaciclib; preferably, for example, palbociclib.

[0180] In a specific embodiment, the BRAF kinase-mediated cancer is a melanoma, a brain tumor such as glioblastoma multiforme (GBM), acute myeloid leukemia (AML), lung cancer, papillary thyroid carcinoma, low-grade ovarian cancer, colorectal cancer, multiple myeloma, and a nervous system cancer. Preferably, the BRAF kinase-mediated cancer is a metastatic or unresectable melanoma, papillary thyroid carcinoma, low-grade ovarian cancer, and colorectal cancer. In a specific embodiment, the BRAF kinase is a BARF V600 mutant kinase. In a specific embodiment, the BRAF V600 mutation is BRAF V600E, BRAF V600D, BRAF V600R, BRAF V600G, and BRAF V600K. In a specific embodiment, the BRAF V600 mutation is BRAF V600E and BRAF V600K. In a specific embodiment, the BRAF kinase-mediated cancer is a metastatic or unresectable melanoma of a BRAF V600 mutation. In a specific embodiment, the BRAF kinase-mediated cancer is a metastatic or unresectable melanoma with a BRAF V600E or BRAF V600K mutation. In a specific embodiment, the BRAF kinase-mediated cancer is a colorectal cancer with a BRAF V600 mutation. In a specific embodiment, the BRAF kinase-mediated cancer is a colorectal cancer with a BRAF V600E or BRAF V600K mutation.

[0181] The present invention also provides a method for treating cancers with NRAS or KRAS or EGFR mutations, comprising administering to the subject a compound of the present invention and an EGFR inhibitor (each optionally in a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate). In a specific embodiment, the EGFR inhibitor is selected from gefitinib, erlotinib, afatinib, dacomitinib, lapatinib, osimertinib, ametinib, vometinib, CO-1686, WZ4002, PD153035, PF00299804, cetuximab, panitumumab, naxituzumab. In a specific embodiment, the cancer with NRAS mutations is non-small cell lung cancer with NRAS mutations. In a specific embodiment, the NRAS mutation is selected from E63K, G12V, G12R, G12A, G12D, G12S and G12C, or an increase in the number of NRAS gene copies.

[0182] The present invention also provides a method for treating advanced KRAS-positive metastatic colorectal cancer, comprising administering to the subject a compound of the present invention in combination with mFOLFIRI (each optionally in a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate).

[0183] The present invention also provides a method for treating gastrointestinal stromal tumors, comprising administering to the subject a compound of the present invention in combination with pexidartinib (each optionally in a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate).

[0184] The present invention also provides a method for treating gastrointestinal stromal tumors, comprising administering to the subject a compound of the present invention in combination with imatinib (each optionally in a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate or solvate).

[0185] The present invention also provides a method for treating non-squamous lung cancer, comprising administering to the subject a compound of the present invention in combination with carboplatin and pemetrexed (each optionally in a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate).

[0186] The present invention also provides a method for treating biliary tract cancer, comprising administering to the subject a compound of the present invention in combination with capecitabine (each optionally in a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate or solvate).

[0187] Example

[0188] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the following examples without specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, parts and percentages are by weight and weight percentage.

[0189] Abbreviations:

[0190] Pd2(dba)3: tris(dibenzylideneacetone)dipalladium

[0191] Xant-phos:4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0192] NBS: N-bromosuccinimide

[0193] NIS: N-iodosuccinimide

[0194] PTSA: p-Toluenesulfonic acid

[0195] EDCI: 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride

[0196] HOBT: 1-Hydroxybenzotriazole

[0197] DMAP: dimethylaminopyridine

[0198] TEA: triethylamine

[0199] DIEA: N,N-diisopropylethylamine

[0200] TFAA: trifluoroacetic anhydride

[0201] Na2CO3: Sodium carbonate

[0202] K2CO3: Potassium carbonate

[0203] Cs2CO3: Cesium carbonate

[0204] EtOH: ethanol

[0205] BnOH: benzyl alcohol

[0206] DCM: dichloromethane

[0207] THF: Tetrahydrofuran

[0208] ACN: Acetonitrile

[0209] DME: Ethylene glycol dimethyl ether

[0210] DMF: N,N-dimethylformamide

[0211] DMSO: dimethyl sulfoxide

[0212] TMSCl: trimethylchlorosilane

[0213] Intermediate A-15-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-(methyl-d3)-1H-benzimidazole-6-carboxylic acid preparation

[0214]

[0215] The following synthetic route was used

[0216]

[0217] Step 1: Synthesis of compound 2,3,4-trifluoro-5-nitrobenzoic acid

[0218] Dissolve 2,3,4-trifluorobenzoic acid (20 g, 113.6 mmol) in 60 ml of concentrated sulfuric acid, heat the reaction solution to 90°C, then drop a mixed solution of concentrated sulfuric acid (12 g, 122.4 mmol) and concentrated nitric acid (12.8 g, 132.1 mmol), stir and react for 5 hours, monitor the reaction by TLC, cool to room temperature, slowly drop the reaction solution into ice water, extract with ethyl acetate 3-4 times, combine the organic phases, wash with saturated brine 2-3 times, dry with anhydrous sodium sulfate, filter and concentrate to obtain 24.0 g of white solid, yield 95.6%. LC-MS (APCI): m / z=220.1 (M-1) - .

[0219] Step 2: Synthesis of compound 2,3-difluoro-4-amino-5-nitrobenzoic acid

[0220] The 2,3,4-trifluoro-5-nitrobenzoic acid (5.81 g, 26.3 mmol) obtained in the previous step was placed in a 100 ml flask, 30 ml of deionized water was added, the mixture was cooled to 0°C in an ice bath, concentrated ammonia (18.4 g, 131.5 mmol) was slowly added dropwise, after the addition was completed, the mixture was heated to room temperature and stirred to react overnight, TLC monitored the completion of the reaction, 1N dilute hydrochloric acid was used to adjust the pH to <2 in an ice bath, and a light yellow solid was precipitated, which was filtered and vacuum dried to obtain 4.99 g of the product, with a yield of 87.1%. LC-MS (APCI): m / z = 219.4 (M+1) + .

[0221] Step 3: Synthesis of compound 2,3-difluoro-4-amino-5-nitrobenzoic acid methyl ester

[0222] Add 2,3-difluoro-4-amino-5-nitrobenzoic acid (4.99 g, 22.9 mmol) and trimethylsilyl chloride (4.97 g, 45.8 mmol) to the reaction flask, add 100 ml of methanol to dissolve, heat the reaction solution to 65°C under nitrogen protection and stir overnight, monitor the reaction by TLC, cool to room temperature, concentrate and separate on a silica gel column to obtain 4.51 g of a yellow solid, with a yield of 84.9%. LC-MS (APCI): m / z = 233.4 (M+1) + .

[0223] Step 4: Synthesis of compound 2,4-diamino-3-fluoro-5-nitrobenzoic acid methyl ester

[0224] The methyl 2,3-difluoro-4-amino-5-nitrobenzoate (1.0 g, 4.3 mmol) obtained in the previous step was dissolved in 10 ml of dioxane, and ammonia water (1.6 ml, 21.4 mmol) was added. The temperature was raised to 90°C under nitrogen protection for 2-4 hours. The reaction was completed after TLC monitoring. The reaction solution was cooled to room temperature, diluted with 30 ml of water, extracted with ethyl acetate 3-4 times, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and dried to obtain 1.03 g of yellow solid, which was directly put into the next step of reaction. LC-MS (APCI): m / z = 230.8 (M+1) + .

[0225] Step 5: Synthesis of compound 2,4,5-triamino-3-fluorobenzoic acid methyl ester

[0226] The methyl 2,4-diamino-3-fluoro-5-nitrobenzoate (1.03 g, 4.5 mmol), reduced iron powder (2.5 g, 45 mmol) and anhydrous ammonium chloride (1.44 g, 26.9 mmol) obtained in the previous step were placed in a 100 ml flask, 15 ml of ethanol and 5 ml of water were added, and the mixture was heated to 70 ° C and stirred for 1-2 hours. The reaction was completed after TLC monitoring. The catalyst was removed by diatomaceous earth filtration, and the filtrate was concentrated to obtain 860 mg of gray solid, which was directly put into the next step without purification. LC-MS (APCI): m / z = 200.1 (M+1) + .

[0227] Step 6: Synthesis of compound 4-fluoro-5-amino-1H-benzimidazole-6-carboxylic acid methyl ester

[0228] The methyl 2,4,5-triamino-3-fluorobenzoate (860 mg, 4.32 mmol) and acetic acid formamidine (542 mg, 5.21 mmol) obtained in the previous step were added to 10 ml of anhydrous ethanol, heated to 80 ° C and refluxed for 4 hours. The reaction was monitored by TLC. The reaction solution was cooled to room temperature, concentrated to remove the solvent, diluted with 20 ml of water, extracted with dichloromethane 3-4 times, and the organic phases were combined, concentrated, and purified by silica gel column chromatography to obtain 486 mg of light yellow solid, with a yield of 53.8%. LC-MS (APCI): m / z = 210.5 (M+1) + .

[0229] Step 7: Synthesis of compound 4-fluoro-5-amino-1-(methyl-d3)-1H-benzimidazole-6-carboxylic acid methyl ester

[0230] The 4-fluoro-5-amino-1H-benzimidazole-6-carboxylic acid methyl ester (600 mg, 2.86 mmol), deuterated iodomethane (458 mg, 3.16 mmol) and potassium carbonate (794 mg, 5.76 mmol) obtained in the previous step were added to a 50 ml reaction bottle, and 10 ml of anhydrous DMF was added. The temperature was raised to 70 ° C under nitrogen protection and stirred for 2 hours. The reaction was monitored by TLC. After cooling to room temperature, 30 ml of water was added for dilution, and ethyl acetate was used for extraction 3-4 times. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and separated by silica gel column to obtain 201 mg of brown solid, with a yield of 31.5%. LC-MS (APCI): m / z = 227.5 (M+1) + .

[0231] Step 8: Synthesis of compound 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-(methyl-d3)-1H-benzimidazole-6-carboxylic acid methyl ester

[0232] The methyl 4-fluoro-5-amino-1-(methyl-d3)-1H-benzimidazole-6-carboxylate (200 mg, 0.9 mmol), 2-fluoro-4-bromo-1-iodobenzene (300 mg, 0.99 mmol), Pd2(dba)3 (16 mg, 0.017 mmol), Xantphos (26 mg, 0.044 mmol) and cesium carbonate (584 mg, 1.79 mmol) obtained in the previous step were added to a 20 ml microwave tube, and 8 ml of ethylene glycol dimethyl ether was added under nitrogen protection. After sealing, the tube was heated to 90° C. in a microwave for 1 hour. The reaction was completed by TLC monitoring, and the mixture was cooled to room temperature and concentrated to remove the solvent. The mixture was purified by silica gel column chromatography to obtain 229 mg of a yellowish brown solid, with a yield of 64.0%. LC-MS (APCI): m / z=399.2 (M+1) + .

[0233] Step 9: Synthesis of Intermediate A-1

[0234] 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-(methyl-d3)-1H-benzimidazole-6-carboxylic acid methyl ester (1.63g, 4.09mmol) was added to a 100ml reaction bottle, 30ml tetrahydrofuran and 10ml water were added to dissolve, and then sodium hydroxide (0.68g, 17.0mmol) was added, and the mixture was heated to 45°C and stirred for 3-5 hours. After the reaction was completed by TLC monitoring, the tetrahydrofuran was removed by concentration, 10ml water was added to dilute, and the pH was adjusted to acidic with 1N dilute hydrochloric acid to precipitate an off-white solid. After filtration, vacuum drying was performed to obtain 1.3g of crude product, which was directly used in the next step of reaction. LC-MS (APCI): m / z=385.2 (M+1) + .

[0235] Intermediate A-25-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid methyl ester Preparation

[0236]

[0237] The following synthetic route was used

[0238]

[0239] Step 1: Synthesis of compound 4-fluoro-5-amino-1-methyl-1H-benzimidazole-6-carboxylic acid methyl ester

[0240] 4-Fluoro-5-amino-1H-benzimidazole-6-carboxylic acid methyl ester (600mg, 2.86mmol), iodomethane (453mg, 3.16mmol) and potassium carbonate (794mg, 5.76mmol) were added to a 50ml reaction bottle, 10ml of anhydrous DMF was added, the temperature was raised to 70°C under nitrogen protection, stirred and reacted for 2 hours, and the reaction was completed after TLC monitoring. After cooling to room temperature, 30ml of water was added to dilute, extracted with ethyl acetate 3-4 times, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated, and separated by silica gel column to obtain 203mg of brown solid, with a yield of 31.9%. LC-MS (APCI): m / z=224.5 (M+1) + .

[0241] Step 2: Synthesis of compound 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid methyl ester

[0242] The methyl 4-fluoro-5-amino-1-methyl-1H-benzimidazole-6-carboxylate (200 mg, 0.9 mmol), 2-fluoro-4-bromo-1-iodobenzene (300 mg, 0.99 mmol), Pd2(dba)3 (16 mg, 0.017 mmol), Xantphos (26 mg, 0.044 mmol) and cesium carbonate (584 mg, 1.79 mmol) obtained in the previous step were added to a 20 ml microwave tube, and 8 ml of ethylene glycol dimethyl ether was added under nitrogen protection. After sealing, the tube was heated to 90° C. in a microwave for 1 hour. The reaction was completed by TLC monitoring, and the mixture was cooled to room temperature and concentrated to remove the solvent. The mixture was purified by silica gel column chromatography to obtain 208 mg of a yellowish brown solid, with a yield of 58.1%. LC-MS (APCI): m / z=396.2 (M+1) + .

[0243] Step 3: Synthesis of intermediate A-2

[0244] 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid methyl ester (1.63g, 4.09mmol) was added to a 100ml reaction bottle, 30ml tetrahydrofuran and 10ml water were added to dissolve, and then sodium hydroxide (0.68g, 17.0mmol) was added, and the mixture was heated to 45°C and stirred for 3-5 hours. After the reaction was completed by TLC monitoring, the tetrahydrofuran was removed by concentration, 10ml water was added to dilute, and the pH was adjusted to acidic with 1N dilute hydrochloric acid to precipitate an off-white solid. After filtration, vacuum drying was performed to obtain 1.3g of crude product, which was directly used in the next step of reaction. LC-MS (APCI): m / z=382.1 (M+1) + .

[0245] Preparation of Intermediate B-12-(Aminooxy)-2,2-dideuteroacetic acid benzyl ester

[0246]

[0247] The following synthetic route was used

[0248]

[0249] Step 1: Synthesis of compound 2-bromo-2,2-dideuteroacetic acid

[0250] Deuterated acetic acid (10 g, 156 mmol) was added to 80 ml of trifluoroacetic anhydride, and a bromine-dioxane complex (37 g, 149 mmol) was added at room temperature. The mixture was stirred and reacted overnight under nitrogen protection. The reaction was completed after GC monitoring. After concentration under reduced pressure, 10.8 g of an oily liquid was obtained, which was directly used in the next step without purification.

[0251] Step 2: Synthesis of compound 2-bromo-2,2-dideuteroacetic acid benzyl ester

[0252] Dissolve 2-bromo-2,2-dideuteroacetic acid (10.8 g, 78.55 mmol), benzyl alcohol (8.5 g, 78.6 mmol), EDCI (16.6 g, 86.6 mmol) and DMAP (1.06 g, 8.7 mmol) in 80 ml of anhydrous DMF, stir at room temperature under nitrogen protection for 3-5 hours, and monitor the completion of the reaction by TLC. Add 200 ml of water to dilute, extract with ethyl acetate 3-4 times, combine the organic phases, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate, and separate on a silica gel column to obtain 7.5 g of anhydrous oily liquid, with a two-step yield of 21%. LC-MS (APCI): m / z=280.3 (M+1) + .

[0253] Step 3: Synthesis of compound 2-((1,3-dioxoisoindolin-2-yl)oxy)-2,2-dideuteroacetic acid benzyl ester

[0254] Add 2-bromo-2,2-dideuteroacetic acid benzyl ester (3.94 g, 17.3 mmol), N-hydroxyphthalimide (2.51 g, 15.38 mmol) and triethylamine (2.36 g, 23.3 mmol) obtained in the previous step to 40 ml of anhydrous DMF and stir at room temperature overnight under nitrogen protection. Add 150 ml of water to dilute, extract with ethyl acetate 3-4 times, combine the organic phases, wash with saturated brine, dry with anhydrous sodium sulfate, concentrate, and separate on a silica gel column to obtain 4.36 g of a white solid with a yield of 81%. LC-MS (APCI): m / z=314.4 (M+1) + .

[0255] Step 4: Synthesis of intermediate B-1

[0256] The 2-((1,3-dioxoisoindolin-2-yl)oxy)-2,2-dideuteroacetic acid benzyl ester (4.36 g, 14.0 mmol) and hydrazine hydrate (1.0 g, 20.0 mmol) obtained in the previous step were dissolved in 45 ml of dichloromethane, stirred at room temperature overnight, and the reaction was monitored by TLC. The insoluble matter was removed by filtration, and the filtrate was concentrated and separated by silica gel column to obtain 1.99 g of yellow oily liquid, with a yield of 78.3%. LC-MS (APCI): m / z = 184.7 (M+1) + .

[0257] Example 15-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy)-1-(methyl-d 3 )-1H- Preparation of benzimidazole-6-carboxamide (Compound T-1)

[0258]

[0259] The following synthetic route was used

[0260]

[0261] Step 1: Synthesis of compound 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-(methyl-d3)-N-(2-(vinyloxy)ethoxy)-1H-benzimidazole-6-carboxamide

[0262] Intermediate A-1 (1.3 g, 3.4 mmol), O-(2-(vinyloxy)ethyl)hydroxylamine (0.41 g, 4.02 mmol), EDCI (0.78 g, 4.06 mmol), HOBT (0.55 g, 4.08 mmol) and triethylamine (0.41 g, 4.06 mmol) were added to a 100 ml reaction bottle, 15 ml of anhydrous DMF was added under nitrogen protection, the reaction was stirred overnight at room temperature, and the reaction was completed after TLC monitoring. 50 ml of water was added to dilute, and the mixture was extracted with ethyl acetate for 3-4 times. The organic phases were combined, washed with saturated brine, concentrated, and purified by silica gel column chromatography to obtain 0.88 g of off-white solid, with a yield of 55.3%. LC-MS (APCI): m / z=470.5 (M+1) + . 1 H NMR (400MHz, DMSO-d6): δ11.79(s,1H),8.39(s,1H),7.92(s,1H),7.71(d,J=13.2Hz,1H),7.61(t,J=9.4Hz,1H),7. 23-7.27(m,1H),6.52-6.43(m,1H),6.35(dd,J=8.7,4.1Hz,1H),4.23-4.10(m,1H),4.06-3.91(m,3H),3.83(s,2H).

[0263] Step 2: Synthesis of compound T-1

[0264] The 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-(methyl-d3)-N-(2-(vinyloxy)ethoxy)-1H-benzimidazole-6-carboxamide (0.88 g, 1.88 mmol) obtained in the previous step was dissolved in 15 ml of ethanol, cooled to 0°C in an ice bath, and 2N dilute hydrochloric acid (9.4 ml, 18.8 mmol) was slowly added dropwise. After the addition was completed, the mixture was heated to room temperature and stirred for 2-4 hours. The reaction was monitored by TLC. The pH was adjusted to weak alkalinity with 1N sodium hydroxide aqueous solution, the solvent was concentrated and removed, and 0.42 g of white solid was purified by silica gel column chromatography. The yield was 50.5%. LC-MS (APCI): m / z=444.7 (M+1) + . 1 H NMR (400MHz, CD3OD): δ8.30(s,1H),8.09(s,1H),7.72(s,1H),7.50(d,J=2.0Hz,1H), 7.21-7.17(m,1H),6.40(dd,J=8.8,4.8Hz,1H),3.97-3.89(m,2H),3.70-3.66(m,2H).

[0265] Example 25-((4-bromo-2-fluorophenyl)amino)-4-fluoro-N-(2-hydroxyethoxy-1,1,2,2-d 4 )-1-A Preparation of 1H-benzimidazole-6-carboxamide (Compound T-2)

[0266]

[0267] The following synthetic route was used

[0268]

[0269] Step 1: Synthesis of compound 2-((5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzimidazole-6-carboxylic acid amino)oxy)-2,2-dideuteroacetic acid benzyl ester

[0270] Intermediate A-2 (1.3 g, 3.4 mmol), intermediate B-1 (0.74 g, 4.02 mmol), EDCI (0.78 g, 4.06 mmol), HOBT (0.55 g, 4.08 mmol) and triethylamine (0.41 g, 4.06 mmol) were added to a 100 ml reaction bottle, 15 ml of anhydrous DMF was added under nitrogen protection, the reaction was stirred overnight at room temperature, and the reaction was completed after TLC monitoring, 50 ml of water was added to dilute, and ethyl acetate was used for extraction 3-4 times. The organic phases were combined, washed with saturated brine, concentrated, and purified by silica gel column chromatography to obtain 1.78 g of off-white solid, with a yield of 95.7%. LC-MS (APCI): m / z=547.3 (M+1) + . 1 H NMR (400MHz, DMSO-d6): δ8.39(s,1H),7.84(s,1H),7.78-7.64(m,1H),7.58(d,J=2.3Hz,1H),7.40 -7.28(m,5H),7.23(dd,J=8.8,2.2Hz,1H),6.32(dd,J=8.7,3.6Hz,1H),5.13(s,2H),3.88(s,3H).

[0271] Step 2: Synthesis of compound T-2

[0272] The 2-((5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benzimidazole-6-formylamino)oxy)-2,2-dideuteroacetic acid benzyl ester (1.78 g, 3.25 mmol) obtained in the previous step was dissolved in 40 ml of anhydrous THF, cooled to -10°C under nitrogen protection, and lithium aluminum hydride (273 mg, 6.5 mmol) was added in batches. The reaction was continued to stir at low temperature for 3-4 hours. After the reaction was completed by TLC monitoring, 5 ml of water was added at low temperature to quench the reaction, and then 10 ml of 15% sodium hydroxide aqueous solution was added. The filtrate was filtered with diatomaceous earth. After the filtrate was concentrated, it was purified by silica gel column chromatography to obtain 0.47 g of an off-white solid, with a yield of 32.6%. LC-MS (APCI): m / z=445.6 (M+1) + . 1 H NMR (400MHz, CD3OD): δ11.73-11.64(m,1H),8.40(s,1H),7.93(brs,1H),7.74(s,1H),7.61(s, 1H), 7.26 (dd, J=8.8Hz, 2.0Hz, 1H), 6.36 (dd, J=8.7Hz, 4.0Hz, 1H), 4.67 (brs, 1H), 3.91 (s, 3H).

[0273] Biological activity testing.

[0274] (1) Cytotoxicity assay

[0275] The inhibitory effect of the example compounds on the activity of HT-29 cells was detected.

[0276] Cell line: HT-29 (cell type: adherent; cell number / well: 3000; culture medium: RPMI-1640+10% FBS;) was cultured at 37°C, 5% CO2, and 95% humidity.

[0277] Consumables and reagents: Fetal bovine serum FBS (GBICO, Cat#10099-141), Luminescent Cell Viability Assay (Promega, Cat# G7572), 96-well clear flat-bottom black wall plate ( Cat#3603).

[0278] Instruments: SpectraMax multi-label microplate reader, MD, 2104-0010A; CO2 incubator, ThermoScientific, Model 3100Series; biological safety cabinet, Thermo Scientific, Model 1300Series A2; inverted microscope, Olympus, CKX41SF; refrigerator, SIEMENS, KK25E76TI.

[0279] Experimental steps:

[0280] 1) Cell culture and inoculation: i) Harvest cells in the logarithmic growth phase and count the cells using a platelet counter. Detect cell viability using the trypan blue exclusion method to ensure that the cell viability is above 90%; ii) Adjust the cell concentration; Add 90 μL of cell suspension to each 96-well plate; iii) Culture the cells in the 96-well plate overnight at 37°C, 5% CO2, and 95% humidity.

[0281] 2) Drug dilution and dosing: i) Prepare a 10-fold drug solution with a maximum concentration of 100 μM, 9 concentrations, and 3.16-fold dilution. Add 10 μL of the drug solution to each well of a 96-well plate seeded with cells, and set up three replicate wells for each drug concentration; ii) Place the cells in the 96-well plate with the drug added at 37°C, 5% CO2, and 95% humidity for a further 72 hours, and then perform CTG analysis.

[0282] 3) Endpoint plate reading: i) Thaw CTG reagent and equilibrate the cell plate to room temperature for 30 minutes; ii) Add an equal volume of CTG solution to each well; iii) Shake on an orbital shaker for 5 minutes to lyse the cells; iv) Place the cell plate at room temperature for 20 minutes to stabilize the luminescence signal; v) Read the luminescence value.

[0283] Data processing: GraphPad Prism 5.0 software was used to analyze the data, and nonlinear S-curve regression was used to fit the data to obtain the dose-effect curve, and the IC50 value was calculated from it. Cell survival rate (%) = (Lum test drug-Lum culture medium control) / (Lum cell control-Lum culture medium control) × 100%.

[0284] The compounds of the present invention were tested in the above cytotoxicity assay, and the results showed that the compounds of the present invention had more potent activity against HT-29 cells compared to the undeuterated compound Binimetinib.

[0285] (2) Metabolic stability evaluation

[0286] Metabolic stability is generally used to describe the speed and extent of a compound's metabolism, and is one of the main factors affecting pharmacokinetic properties. Many compounds are substrates for CYP450 enzymes and other drug-metabolizing enzymes, and liver microsomes are a system rich in CYP450. The purpose of this experiment is to study the in vitro metabolic stability of the compound by incubating it with human liver microsomes and / or mouse liver microsomes and using LC-MS / MS to detect the remaining proportion of the compound.

[0287] ① Preparation of solution

[0288] Phosphate buffered saline (PBS): Mix 150 mL of pre-prepared KH2PO4 (0.5 M) solution and 700 mL of K2HPO4 (0.5 M) solution, and adjust the pH value of the mixture to 7.4 with K2HPO4 (0.5 M) solution to prepare 5-fold PBS, and store at 4°C for later use. Dilute 5-fold with ultrapure water before use, and add 3.3 mM magnesium chloride to obtain phosphate buffered saline (PBS) (100 mM).

[0289] NADPH regeneration system solution: Use 5 mL of PBS to prepare an NADPH solution containing 6.5 mM NADP, 16.5 mM G-6-P, and 3 U / mL G-6-PD.

[0290] Internal standard stop solution: Prepare 50 ng / mL propranolol hydrochloride and 200 ng / mL tolbutamide in acetonitrile as internal standard working solution.

[0291] Human liver microsome solution: Take 0.31 mL of human liver microsomes (25 mg / mL) and add them to 0.961 mL of PBS (pH 7.4) and mix well to obtain a human liver microsome dilution solution with a protein concentration of 0.625 mg / mL.

[0292] Mouse liver microsome solution: Take 0.31 mL of mouse liver microsomes (25 mg / mL) and add them to 0.961 mL of PBS (pH 7.4) and mix well to obtain a mouse liver microsome dilution solution with a protein concentration of 0.625 mg / mL.

[0293] Sample working solution: The compound of the present invention and non-deuterated compound powder, positive control dextromethorphan powder and omeprazole powder were prepared with DMSO to 10 mM as sample stock solution, and then diluted with 70% acetonitrile-water to obtain 0.25 mM sample working solution.

[0294] ②Sample incubation

[0295] 398 μL of human liver microsome dilution was added to a 96-well incubation plate (N=2), and 2 μL of 0.25 mM test compound and dextromethorphan were added respectively and mixed.

[0296] 398 μL of mouse liver microsome dilution was added to a 96-well incubation plate (N=2), and 2 μL of 0.25 mM test compound and dextromethorphan were added respectively and mixed.

[0297] Add 300 μL of pre-cooled stop solution to each well of a 96-well deep-well plate and place on ice to serve as a stop plate.

[0298] Place the 96-well incubation plate and NADPH regeneration system in a 37°C water bath, shake at 100 rpm, and pre-incubate for 5 minutes. Take out 80 μL of incubation solution from each well of the incubation plate and add it to the termination plate, mix well, and add 20 μL of NADPH regeneration system solution as the 0min sample. Add 80 μL of NADPH regeneration system solution to each well of the incubation plate, start the reaction, and start timing. The reaction concentration of the test compound is 1 μM, and the protein concentration is 0.5 mg / mL.

[0299] At 10, 30, and 90 min of reaction, 100 μL of the reaction solution was taken and added to the stop plate, and vortexed for 3 min to terminate the reaction.

[0300] The stop plate was centrifuged at 5000 rpm and 4°C for 15 min. 200 μL of supernatant was taken into a 96-well plate pre-added with 200 μL of ultrapure water, mixed well, and sampled by LC-MS / MS, injecting 10 uL.

[0301] ③Sample analysis method

[0302] In this experiment, the LC-MS / MS system was used to detect the peak areas of the test compound, dextromethorphan, omeprazole and internal standard, and the peak area ratio of the compound to the internal standard was calculated.

[0303] ④Data processing

[0304] The peak areas of the samples and internal standards were obtained by mass spectrometer and Analyst software. The residual amount of the compound (R%) and time were plotted using the single exponential degradation model of Graphpad prism7.0 software to obtain the substrate elimination rate constant K.

[0305] C t / C0=exp(-K*t)

[0306] The half-life T is calculated according to the following formula: 1 / 2 and intrinsic clearance CL int , where V / M is equal to 1 / C(protein).

[0307] T 1 / 2 (min); CL int (μL / min / mg).

[0308] Experimental results: The compounds of the present invention and their non-deuterated compounds were tested and compared to evaluate their metabolic stability in human and / or mouse liver microsomes. Compared with the non-deuterated compound Binimetinib, the compounds of the present invention have a longer half-life T 1 / 2 and lower clearance CL int The results of the exemplary compounds are summarized in Tables 1 and 2.

[0309] Table 1:

[0310]

[0311]

[0312] Table 2:

[0313]

[0314] (3) Pharmacokinetic experiments in rats

[0315] Six male Sprague-Dawley rats, 7-8 weeks old, weighing about 210 g, were divided into two groups, 3 rats in each group, and a single dose of the compound (10 mg / kg orally) was administered intravenously or orally to compare the pharmacokinetic differences.

[0316] Rats were fed with standard diet and given water. Fasting began 16 hours before the experiment. Drugs were dissolved with PEG400 and dimethyl sulfoxide. Blood was collected from the orbit at 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, and 24 hours after administration.

[0317] The rats were briefly anesthetized by inhalation of ether, and 300 μL of blood was collected from the orbits into test tubes. The test tubes contained 30 μL of 1% heparin saline solution. Before use, the test tubes were dried at 60°C overnight. After the last time point of blood sampling, the rats were killed under ether anesthesia.

[0318] After blood sample collection, gently invert the test tube at least 5 times to ensure sufficient mixing and place on ice. The blood sample is centrifuged at 5000rpm for 5 minutes at 4°C to separate plasma from red blood cells. Use a pipette to aspirate 100μL of plasma into a clean plastic centrifuge tube and mark the name of the compound and time point. The plasma is stored at -80°C before analysis. The concentration of the compound of the present invention in plasma is determined by LC-MS / MS. Pharmacokinetic parameters are calculated based on the blood drug concentration of each animal at different time points.

[0319] Experiments show that, compared with the non-deuterated compound Binimetinib, the compound of the present invention has better pharmacokinetic properties in animals, and therefore has better pharmacodynamics and therapeutic effects.

[0320] The above contents are further detailed descriptions of the present invention in combination with specific preferred embodiments, and it cannot be determined that the specific implementation of the present invention is limited to these descriptions. For ordinary technicians in the technical field to which the present invention belongs, several simple deductions or substitutions can be made without departing from the concept of the present invention, which should be regarded as falling within the protection scope of the present invention.

Claims

1. A compound of formula (II), or a pharmaceutically acceptable salt thereof: in, Y1 is hydrogen; R1, R2, R3 and R4 are each independently selected from hydrogen or deuterium; X is selected from CH3 or CD3; The additional condition is that X is CD3 when R1 and R2 are both deuterium, and / or R3 and R4 are both deuterium, or R1, R2, R3 and R4 are both hydrogen.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are deuterium.

3. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are deuterium.

4. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein R3 and R4 are deuterium.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein: X is CD3.

6. The compound according to claim 1, which is selected from the following compounds: or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition of claim 7, further comprising an additional therapeutic agent.

9. The pharmaceutical composition according to claim 8, wherein The additional therapeutic agent is selected from one or more of a BRAF inhibitor, an EGFR inhibitor, an EGFR antibody, an immune checkpoint inhibitor or a CDK4 / 6 inhibitor.

10. The pharmaceutical composition according to claim 9, wherein The BRAF inhibitor is selected from vemurafenib, dabrafenib, coniferinib, (S)-methyl-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(methyl-d3)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, -1-(propan-2-yl-d7)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate, (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamic acid methyl ester, (S)-(1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonylamino)phenyl)-1-(propan-2-yl-d7))-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl-1,1,3,3,3-d5)carbamic acid methyl ester.

11. The pharmaceutical composition according to claim 9, wherein The EGFR inhibitor is selected from gefitinib, erlotinib, afatinib, dacomitinib, lapatinib, osimertinib, ametinib, vometinib, CO-1686, WZ4002, PD153035, and PF00299804.

12. The pharmaceutical composition according to claim 9, wherein The EGFR antibody is selected from the group consisting of cetuximab, panitumumab, and necituzumab.

13. The pharmaceutical composition according to claim 9, wherein The immune checkpoint inhibitor is selected from pembrolizumab, ipilimumab, nivolumab, atezolizumab, avelumab, durvalumab, and piridilizumab.

14. The pharmaceutical composition according to claim 9, wherein The CDK4 / 6 inhibitor is selected from palbociclib, ribociclib, and abemaciclib.

15. Use of the compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, or the pharmaceutical composition according to any one of claims 7 to 14, in the preparation of a medicament for treating a disease mediated by MEK kinase.

16. The use according to claim 15, wherein The disease mediated by MEK kinase is selected from melanoma, acute myeloid leukemia, glioma, neurofibroma, non-small cell lung cancer, breast cancer, serous carcinoma, gastrointestinal stromal tumor, non-squamous lung carcinoma, colorectal cancer, biliary tract cancer, myeloma.

17. The use according to claim 16, wherein The melanoma is selected from melanomas with BRAF V600 mutation.

18. The use according to claim 16, wherein The colorectal cancer is selected from BRAF V600 mutant colorectal cancer.

19. The use according to claim 16, wherein The neurofibroma is selected from neurofibromatosis type 1 or plexiform neurofibroma.

20. The use according to claim 17 or 18, wherein The BRAF V600 mutation is selected from a BRAF V600E or BRAF V600K mutation.